Urolithin A is a gut microbiome-derived compound that activates mitophagy — the cellular recycling of damaged mitochondria — and has shown measurable benefits for muscle endurance, inflammation, and immune aging in multiple human trials, available through TelosRX longevity programs subject to medical evaluation.
Among the compounds gaining serious traction in longevity research, urolithin A stands out: unlike many longevity molecules that show promise only in animal studies, it has been tested in human randomized controlled trials across multiple endpoints. Here's what the peer-reviewed literature actually shows.
What Is Urolithin A?
Urolithin A (UA) is a postbiotic — a bioactive compound produced when gut bacteria metabolize ellagitannins found in pomegranates, walnuts, and certain berries. The conversion is performed by specific gut microbiota species (notably Gordonibacter urolithinfaciens and Ellagibacter isourolithinifaciens), and critically, only about 40% of the population produces meaningful amounts of UA from dietary sources due to interindividual gut microbiome variation.
This bioavailability gap is why direct UA supplementation — as a standardized oral compound — has become a focus of longevity research: it bypasses gut microbiome dependency to deliver consistent systemic exposure. UA's primary mechanism is induction of mitophagy — the selective autophagy pathway that removes dysfunctional mitochondria and promotes biogenesis of healthy replacements.
Finding 1: Mitophagy Activation in Human Skeletal Muscle
The foundational human study of urolithin A was published in Nature Metabolism in 2019 (Andreux et al., PMID 32694802). In a dose-escalation trial, 60 sedentary older adults received UA (250–2,000 mg) or placebo for 4 weeks. Results showed:
- Dose-dependent increases in mitophagy-related gene expression in skeletal muscle
- Significant upregulation of mitochondrial biogenesis markers (PGC-1α, TFAM) at 500 mg and above
- Favorable safety and tolerability profile across all doses
- Plasma UA levels proportional to dose, confirming systemic absorption
This was the first human evidence that UA could activate mitophagy at the tissue level — not just in cell culture or animal models — making it a landmark study in the longevity supplements space.
Finding 2: Muscle Endurance Improvement in Older Adults
A 2022 randomized controlled trial published in JAMA Network Open (Liu et al., PMID 35050355) extended the mechanistic findings into a functional endpoint. In this 4-month trial, 88 older adults (65–90 years) received UA 1,000 mg daily or placebo. Key findings:
- Statistically significant improvement in 6-minute walk distance in the UA group vs. placebo
- Improved VO2 max and aerobic endurance on cycle ergometer testing
- Reduction in fatigue scores on validated questionnaires
- No significant changes in lean body mass, suggesting functional improvements preceded structural changes
The separation between functional improvement and unchanged lean mass is mechanistically consistent with mitophagy-driven quality improvement in existing muscle tissue: better mitochondrial health means more efficient energy production per unit of muscle mass, not necessarily more mass itself.
Finding 3: Systemic Anti-Inflammatory Effects
Chronic low-grade inflammation — "inflammaging" — is a central driver of biological aging. A 2024 review in Ageing Research Reviews (Hodzic et al.) synthesized UA's anti-inflammatory evidence across preclinical and early clinical studies, identifying consistent suppression of:
- NF-κB pathway activation (the master regulator of inflammatory gene expression)
- TNF-α and IL-6 levels in models of metabolic inflammation
- NLRP3 inflammasome activation, a critical driver of age-related tissue inflammation
UA's anti-inflammatory effects appear partly indirect: by clearing dysfunctional mitochondria that release damage-associated molecular patterns (DAMPs), mitophagy reduces one of the key upstream triggers of chronic sterile inflammation.
Finding 4: Immune Aging and T Cell Rejuvenation
A 2025 randomized trial published in Nature Aging examined UA's effects on immune aging markers in 60 older adults over 12 weeks. Key findings included:
- Significant increase in naive T cell proportions relative to exhausted/senescent T cells
- Improved mitochondrial membrane potential in T cells, consistent with mitophagy-driven quality improvement
- Reduction in p21+ senescent T cells in the UA group vs. placebo
- No serious adverse events; tolerability comparable to placebo
The immune aging angle adds a clinically relevant dimension: a declining ratio of naive to exhausted T cells is associated with reduced vaccine response, increased infection susceptibility, and elevated cancer risk. For related cellular energy support strategies, see our article on NAD+ therapy for cellular health and research on MOTS-c mitochondrial peptide.
Finding 5: Connective Tissue and Joint Health
A 2022 study in Aging Cell (D'Amico et al., PMID 35778837) examined UA's effects in a preclinical osteoarthritis model and cultured chondrocytes. UA supplementation reduced cartilage degradation markers, suppressed MMP-13, and promoted chondrocyte survival under inflammatory conditions. For related peptide research in connective tissue health, see our guide on humanin peptide and mitochondrial longevity.
How Urolithin A Compares to Other Longevity Compounds
| Compound | Primary Mechanism | Human Trial Evidence | Key Strength |
|---|---|---|---|
| Urolithin A | Mitophagy induction, mitochondrial biogenesis | Multiple RCTs (muscle endurance, immune aging, safety) | Direct human functional endpoints; mitophagy specificity |
| NAD+ precursors (NMN/NR) | NAD+ repletion, sirtuin activation | Early-phase human trials; functional data emerging | Broad metabolic signaling; extensively studied mechanistically |
| CoQ10 | Mitochondrial electron transport chain support, antioxidant | RCTs in cardiovascular and fatigue populations | Long safety record; cardiovascular evidence |
| MOTS-c | Mitochondrial peptide, AMPK activation, metabolic regulation | Primarily preclinical; early human data emerging | Novel mitochondrial signaling; promising metabolic data |
Interested in evidence-based longevity support? Explore TelosRX's longevity programs — connect with a licensed provider who can review your biomarkers and design a plan appropriate for your health profile, subject to medical evaluation.
Frequently Asked Questions
What does urolithin A do in the body?
Urolithin A activates mitophagy — the selective removal and recycling of damaged mitochondria — while also promoting mitochondrial biogenesis. This dual action improves mitochondrial quality in tissues throughout the body, with demonstrated effects on muscle endurance, immune cell function, and inflammatory signaling in human trials.
How much urolithin A should I take for longevity?
The 2022 JAMA Network Open trial used 1,000 mg daily and showed significant muscle endurance improvements. The 2019 Nature Metabolism trial showed mitophagy activation beginning at 500 mg. Optimal dosing should be determined with a licensed provider based on your health profile.
Can you get enough urolithin A from pomegranates?
Most people cannot. Only about 40% of the population produces meaningful urolithin A from dietary ellagitannins due to interindividual gut microbiome variation. Even in individuals who do convert, dietary amounts are substantially lower than the doses used in clinical trials.
Is urolithin A FDA-approved?
Urolithin A is not FDA-approved as a drug. It is available as a dietary supplement and is not subject to the same premarket review process as prescription medications. Quality and purity vary significantly by manufacturer.
What is the difference between urolithin A and NAD+ supplements?
Urolithin A primarily drives mitophagy — selective removal of dysfunctional mitochondria — while NAD+ precursors (NMN, NR) restore NAD+ levels to support sirtuin and PARP enzyme activity. The two pathways are complementary: UA addresses mitochondrial quality control while NAD+ supports metabolic signaling.
Can urolithin A improve muscle strength?
The 2022 JAMA Network Open RCT showed significant improvement in muscle endurance (6-minute walk distance, VO2 max) but not muscle mass in older adults after 4 months. UA may improve the functional efficiency of existing muscle before driving structural hypertrophy.
—
This article is for informational purposes only and does not constitute medical advice. Supplements are not FDA-approved drugs. All treatments are subject to medical evaluation and approval by a licensed healthcare provider. TelosRX connects patients with licensed providers who make independent clinical judgments. Individual results vary. Consult your healthcare provider before starting any new supplement or treatment program.